Logo

Eurofins Genomics Extremers

Dec 12, 2016

Eurofins Genomics has launched its Extremer line of "extremely long" oligonucleotides in the US.

The company developed the oligos on its new DNA synthesis platform using high-fidelity chemistry for synthetic biology, next-generation DNA sequencing, and other applications.

Specific uses might include constructing genes with low sequence variability segments; templating in vitro transcription of RNA molecules; introducing large-scale or multi-site mutations; and generating oligos for DNA-directed RNA interference, capture probes, or qPCR control standards.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.